Abstract
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer-related death. Because of the fast growth, early hepatic metastasis and the multidrug resistance, the five-year survival rate is very low. Thus, the understanding of its biology can significantly contribute in identifying valuable targets for novel therapeutic approaches. In this regard, E2F1 may represent an interesting candidate. E2F1 is a transcription factor implicated in the regulation of many cellular processes including cell proliferation and apoptosis. Whereas the involvement of E2F1 in HCC has been recognized, its ability to act as a proliferative and/or apoptotic factor in HCC has not yet been clarified and, in this regard, an active debate is ongoing. The definition of E2F1 role in HCC is not a trivial aspect as it can have significant consequences for the development of novel therapeutic options with E2F1 as target. In this review, we present data about the reported proliferative/apoptotic effects as well as the dual (combined proliferation and apoptosis) functions of E2F1 in HCC discussing the molecular basis for this behavior. The data available so far indicate that the proliferative and apoptotic functions of E2F1 in HCC may coexist but the proliferative effect seems to be more pronounced than the apoptotic one.
Current Drug Delivery
Title:The Role of the Transcription Factor E2F1 in Hepatocellular Carcinoma
Volume: 14 Issue: 2
Author(s): Rossella Farra, Gabriele Grassi, Federica Tonon, Michela Abrami, Mario Grassi, Gabriele Pozzato, Nicola Fiotti, Giancarlo Forte and B. Dapas
Affiliation:
Keywords: Apoptosis, E2F1, HCC, miRNA, proliferation, p53.
Abstract: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer-related death. Because of the fast growth, early hepatic metastasis and the multidrug resistance, the five-year survival rate is very low. Thus, the understanding of its biology can significantly contribute in identifying valuable targets for novel therapeutic approaches. In this regard, E2F1 may represent an interesting candidate. E2F1 is a transcription factor implicated in the regulation of many cellular processes including cell proliferation and apoptosis. Whereas the involvement of E2F1 in HCC has been recognized, its ability to act as a proliferative and/or apoptotic factor in HCC has not yet been clarified and, in this regard, an active debate is ongoing. The definition of E2F1 role in HCC is not a trivial aspect as it can have significant consequences for the development of novel therapeutic options with E2F1 as target. In this review, we present data about the reported proliferative/apoptotic effects as well as the dual (combined proliferation and apoptosis) functions of E2F1 in HCC discussing the molecular basis for this behavior. The data available so far indicate that the proliferative and apoptotic functions of E2F1 in HCC may coexist but the proliferative effect seems to be more pronounced than the apoptotic one.
Export Options
About this article
Cite this article as:
Farra Rossella, Grassi Gabriele, Tonon Federica, Abrami Michela, Grassi Mario, Pozzato Gabriele, Fiotti Nicola, Forte Giancarlo and Dapas B., The Role of the Transcription Factor E2F1 in Hepatocellular Carcinoma, Current Drug Delivery 2017; 14 (2) . https://dx.doi.org/10.2174/1567201813666160527141742
DOI https://dx.doi.org/10.2174/1567201813666160527141742 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-Based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access to both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Extracellular Vesicles as Drug Delivery Systems.
Extracellular vesicles (EVs) are membranous vesicles released from almost all types of cells into extracellular space. EVs are categorized into different types including exosome (~30-150 nm), microvesicle or microparticle (~100-1,000 nm), apoptotic body (~1,000-5,000 nm), and others produced by different mechanisms. Since EVs bear the molecules (e.g., specific lipids, carbohydrates, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiolabeled Probes Targeting G-Protein-Coupled Receptors for Personalized Medicine
Current Pharmaceutical Design <i>In Vivo</i> Anti-Tumor Effects of Flavokawain A in 4T1 Breast Cancer Cell-Challenged Mice
Anti-Cancer Agents in Medicinal Chemistry The First Total Synthesis of Tarennane, a Potent Antioxidant Chalcone Constituent from Tarenna Attenuate or Magnolia Officinalis
Letters in Organic Chemistry Sleep Related Disorders in the Elderly: An Overview
Current Respiratory Medicine Reviews Biological Activities of Yarrow Species (Achillea spp.)
Current Pharmaceutical Design Pharmacological Potential of Sulindac and Its Active Metabolite: A Comprehensive Review
Current Drug Therapy 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity
Anti-Cancer Agents in Medicinal Chemistry Identification of Multi-kinase Allosteric Inhibitors of Oncogenic Targets EGFR1, PI3K, and BRAF Kinase
Current Computer-Aided Drug Design Differentiation-Inducing Therapy for Solid Tumors
Current Pharmaceutical Design Chemoresistance in High-Grade Gliomas: Relevance of Adenosine Signalling in Stem-Like Cells of Glioblastoma Multiforme
Current Drug Targets Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
Current Pharmaceutical Design Upregulation of Focal Adhesion Kinase by 14-3-3ε via NFκB Activation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Dietary Polyphenols for Prostate Cancer Therapy
Current Bioactive Compounds Novel Pharmacologic Approaches to the Management of Sepsis: Targeting the Host Inflammatory Response
Recent Patents on Inflammation & Allergy Drug Discovery Gene Selection for the Discrimination of Colorectal Cancer
Current Molecular Medicine A Critical Approach of Guideline Therapeutic Recommendations for NAFLD
Current Vascular Pharmacology Nucleic Acid Aptamers Against Protein Kinases
Current Medicinal Chemistry Asialoglycoprotein Receptor-Targeted Radiopharmaceuticals for Measurement of Liver Function
Current Medicinal Chemistry Adrenomedullin: A Tumor Progression Factor via Angiogenic Control
Current Cancer Drug Targets Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis
Current Molecular Pharmacology